PM - Philip Morris International Inc.
| Previous Close | 84.79 |
| Open | 84.39 |
| Bid | 83.66 x 1000 |
| Ask | 83.66 x 800 |
| Day's Range | 83.42 - 84.74 |
| 52 Week Range | 64.67 - 92.74 |
| Volume | 1,966,921 |
| Avg. Volume | 6,747,103 |
| Market Cap | 130.04B |
| Beta (3Y Monthly) | 1.03 |
| PE Ratio (TTM) | 17.42 |
| EPS (TTM) | 4.80 |
| Earnings Date | Feb. 5, 2020 - Feb. 10, 2020 |
| Forward Dividend & Yield | 4.68 (5.52%) |
| Ex-Dividend Date | 2019-09-24 |
| 1y Target Est | 91.50 |
- Zacks
Why Is Philip Morris (PM) Up 6.2% Since Last Earnings Report?
Philip Morris (PM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Sysco (SYY) Hikes Dividend: What Else You Should Know?
Sysco (SYY) announces a 15% hike in its quarterly dividend, taking it from 39 cents a share to 45 cents. This marks the 51st hike for the company.
- Zacks
Sysco Adds Hawaiian Distributors to FreshPoint Business
Buyouts of Armstrong Produce and Kula Produce are likely to strengthen Sysco's (SYY) distribution network in Hawaii.
- Yahoo Finance
'We vape. We vote': Pro-vaping groups protest flavor ban
E-cigarette activists take to the streets of Washington DC to protest a proposed flavor ban.
- Zacks
Tyson Foods (TSN) Q4 Earnings Miss Estimates, Sales up Y/Y
Tyson Foods' (TSN) fourth-quarter fiscal 2019 results gain from improved sales in chicken, pork and prepared foods unit. However, sales decline in the beef unit is a drag.
- Zacks
Is Philip Morris International (PM) Stock Outpacing Its Consumer Staples Peers This Year?
Is (PM) Outperforming Other Consumer Staples Stocks This Year?
- Reuters
Trump to meet with vaping industry on vaping, e-cigarettes
U.S. President Donald Trump said on Monday he will be meeting with vaping industry officials as well as medical and political officials to discuss vaping and e-cigarettes. "Will be meeting with representatives of the Vaping industry, together with medical professionals and individual state representatives, to come up with an acceptable solution to the Vaping and E-cigarette dilemma. Trump did not give a time for the meeting.
- Zacks
Philip Morris Trims View on Berlin Plant Closure Charges
Charges of almost $355 million related to the closure of Berlin plant compel Philip Morris (PM) to trim 2019 earnings view. It now expects earnings of $4.53.
- Business Wire
Philip Morris International Inc. Revises, Only for Manufacturing Restructuring Charges in Germany of $0.20 Per Share, Its 2019 Full-Year Reported Diluted EPS Forecast to at Least $4.53 vs. $5.08 in 2018,
Reflecting Ex-Currency Like-for-Like Adjusted Diluted EPS Growth of at Least 9.0%
- Market Realist
Altria Gives Juul Labs Update, Stock Gets Beating
When Altria posted its earnings yesterday, things looked positive. However, after news about Juul Labs, MO stock lost momentum and closed 2.6% lower.
- Market Realist
Why Altria Could Jump on Its Q3 Earnings Beat
Altria (MO) posted better-than-expected third-quarter earnings results today. As expected, lower cigarette shipment volumes remained a drag.
- Zacks
JUUL Continues to Unravel as Altria's (MO) Q3 Earnings Near
Altria (MO) is set to report its third quarter results on Thursday, October 31 before the opening bell.
- Market Realist
Altria in Q3: What Analysts Expect from Its Earnings
Altria (MO) is scheduled to report its third-quarter earnings results on October 31. Analysts expect its earnings to continue to improve year-over-year.
- Zacks
Will Pricing be an Upside for Altria (MO) in Q3 Earnings?
Gains from pricing and savings efforts are likely to be reflected on Altria's (MO) Q3 results. However, receding cigarette sales volumes are a concern.
- Market Realist
Altria Stock: Will Sluggishness End with Q3 Earnings?
Altria stock has recovered sharply in October. There's positive momentum in the stock before the company's earnings. The stock has risen 14% in October.
- Bloomberg
Snus Can Save People From Cigarettes. Just Ask Sweden.
(Bloomberg Opinion) -- Tuesday was an important day for public health in the U.S. For the first time ever, the Food and Drug Administration ruled that a company will be allowed to advertise its tobacco products as less harmful than cigarettes. As momentous as this decision is — and it is momentous — the public health community was not exactly cheering the news. In fact, it was downright grumpy about the whole thing.The products in question are snus. Swedish Match AB, a company that sells cigars, lighters, and chewing tobacco makes snus. (The company divested its cigarettes business in 1999.) Snus users ingest nicotine by placing a small pouch filled with tobacco in between their teeth and their lips. Nicotine can be addictive, but snus aren’t lethal like cigarettes.According to Swedish Match, the Swedes have been using snus since the 1600s. In the years after World War II, snus were overtaken by cigarettes. But after the dangers of smoking became irrefutable, the Swedish government imposed hefty taxes on cigarettes. This caused many smokers to gravitate back to snus; Swedish Match estimates that 9% of Swedish men smoke, while about 18% use snus.The health consequences have been nothing short of amazing. Swedish men have the lowest rate of lung and oral cancer in Europe. A paper published in 2014 by the National Institutes of Health reported that this “mortality advantage” was directly attributable to “the degree of dominance of snus use in the different age groups of Swedish men.” Swedish women, who have not adopted snus like men have, had higher tobacco-related mortality rates.In 2009, President Barack Obama signed the Family Smoking Prevention and Tobacco Control Act, giving the FDA the ability to set standards for tobacco products “to protect the public health.” All tobacco products that came to market after the passage of the new law, including e-cigarettes, would have to be approved by the agency. (The deadline for submitting tobacco products for FDA approval has been repeatedly delayed. It is now set for May 2020.) The FDA also gained the authority to designate a “Modified Risk Tobacco Product” — again, if it deemed the product to be helpful in protecting the public health.Well ahead of every other company, Swedish Match received FDA approval for its snus, sold under the General Snus brand, in November 2015. It was also the first company to apply for the modified-risk designation. Alas, in 2016, its initial effort was turned down. Swedish Match re-applied. And that application is the one the FDA approved on Tuesday.What does it mean? Simply put, it means that the company will be able to say that smokers who use General Snus are less likely to get lung cancer, mouth cancer, heart disease, stroke, emphysema and chronic bronchitis. Are snus completely safe? No. But they are safer than cigarettes. That is the classic definition of a reduced-harm product.There are strict limits about where Swedish Match can make this claim. It can’t advertise on TV. It can’t say it on the packaging. It can make the reduced-harm claim at the point of sale, on its website and in certain other controlled venues. Before it can do anything, it has to submit a marketing plan to the FDA.Given the limitations on Swedish Match’s ability to get the word out, what the company needs now are some credible advocates willing to urge smokers to switch to snus. And while you might think that should be a job for the tobacco control community — which, after all, wants to eliminate smoking — it has been less than enthusiastic.In May, five major anti-tobacco groups sent comments to the FDA, saying that Swedish Match’s application should be denied. Their primary worry was that if the company started marketing snus as modified-risk, kids would start using them. They also said that there was no evidence that adult Americans would use snus the same way Swedes do.The FDA says that snus haven’t been shown to appeal to kids and Swedish Match has vowed not to market to them. Indeed, the FDA has the ability to take away its modified-risk designation for snus if it believes Swedish Match is trying to lure kids.When I called around on Tuesday, it was clear that anti-tobacco advocates' concerns were intact, however. The Campaign for Tobacco-Free Kids sent me a statement from its president, Matt Myers (Bloomberg Philanthropies supports the Campaign for Tobacco-Free Kids). “The FDA must insure that snus tobacco products are not marketed to or used by kids,” he said. The American Lung Association declined comment. The American Heart Association sent me a link to a study that claimed that children are more likely to have higher blood pressure by age 6 if their mothers used snus during pregnancy.There are going to be more companies applying for modified-risk designations. Philip Morris International Inc. already has one in the pipelines, called IQOS, which heats tobacco but doesn’t burn it. For all their current problems, the e-cigarette companies will also eventually seek a modified risk label from the FDA. This is the Holy Grail: to be able to say publicly that their products are less harmful than cigarettes.The evidence from Sweden is indisputable: Snus save lives. Anti-smoking advocates could make a credible case for supporting them, thereby improving public health. Instead, even with the modified-risk designation, Swedish Match is going to have a tough time getting the word out to the people who need to hear it: the 35 million adult smokers in the U.S.It’s a funny thing. In Europe, people are far less worried about e-cigarettes than people in the U.S. The British, in fact, have embraced e-cigarettes as healthier alternative to smoking. But snus? Believe it or not, they are banned in most of Europe.To contact the author of this story: Joe Nocera at jnocera3@bloomberg.netTo contact the editor responsible for this story: Timothy L. O'Brien at tobrien46@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Joe Nocera is a Bloomberg Opinion columnist covering business. He has written business columns for Esquire, GQ and the New York Times, and is the former editorial director of Fortune. His latest project is the Bloomberg-Wondery podcast "The Shrink Next Door."For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
- Yahoo Finance
Expert witnesses in Big Tobacco cases explain why Juul doesn’t have a ‘get out of jail free card’
As federal and state-level investigations into vaping companies like Juul pile up, experts who testified in Big Tobacco cases say a similar storm is brewing.
- Market Realist
Will Altria Erase Its Losses and Turn Positive?
On October 18, Citigroup upgraded Altria stock to “neutral” from “sell.” It expects the negative news surrounding vaping to boost cigarette volumes.
- Thomson Reuters StreetEvents
Edited Transcript of PM earnings conference call or presentation 17-Oct-19 1:00pm GMT
Q3 2019 Philip Morris International Inc Earnings Call
- Market Realist
Philip Morris: Earnings Beat, Sales Lag in Q3
Philip Morris reported mixed third-quarter results before the markets opened. The company posted revenues of $7.64 billion—up 1.8% YoY.
- Zacks
Philip Morris (PM) Q3 Earnings Top Estimates, Sales Improve Y/Y
Philip Morris' (PM) Q3 results gain from growth in heated tobacco unit and favorable pricing. However, decline in cigarette shipment volumes was a drag.
- Zacks
Philip Morris (PM) Beats Q3 Earnings and Revenue Estimates
Philip Morris (PM) delivered earnings and revenue surprises of 5.93% and 0.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Philip Morris International Inc. Reports 2019 Third-Quarter Results
Revises, for a Tax Charge of $0.20 Per Share in Russia, 2019 Full-Year Reported Diluted EPS Forecast to at Least $4.73 vs. $5.08 in 2018, Reflecting Currency-Neutral Like-For-Like
- Investing.com
Philip Morris Earnings Beat, Revenue Misses In Q3
Investing.com - Philip Morris reported third quarter earnings that beat analysts' expectations on Thursday and revenue that fell short of forecasts.
- Investing.com
Top 5 Things to Know in the Market on Thursday
Investing.com -- There's a Brexit deal in the offing, although it still needs to be approved by a recalcitrant British parliament. The pound and other U.K. and European assets are responding with enthusiasm. Elsewhere, Netflix (NASDAQ:NFLX) is set for a pop after stronger-than-expected earnings in the third quarter, even though subscriber growth again fell short of expectations. There are also regular updates on U.S. industrial production and the housing market, while oil is struggling after a big build in U.S. crude stocks last week. Here's what you need to know in financial markets on Thursday, 17th October.
